Alpha Paradigm Partners, LLC Tcr2 Therapeutics Inc. Transaction History

Alpha Paradigm Partners, LLC

  • $239 Million
  • Q4 2022

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021
SELL
$8.44 - $18.35 $129,478 - $281,507
-15,341 Closed
0 $0
Q2 2021

Aug 13, 2021
BUY
$16.41 - $24.71 $251,745 - $379,076
15,341 New
15,341 $252 Million

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Alpha Paradigm Partners, LLC Portfolio

Follow Alpha Paradigm Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Paradigm Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Paradigm Partners, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email